SCOTTSDALE, Ariz., June 9 /PRNewswire-FirstCall/ -- Research and development biotechnology company ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. , has named Moshe Arditi, MD, as Senior Advisor to its recently established Bioterrorism Preparedness Advisory Board. Moshe Arditi, MD, is Director of the Division of Pediatric Infectious Diseases at Cedars-Sinai Medical Center. In addition, he is a Professor of Pediatrics at the University of California, Los Angeles (UCLA), School of Medicine.
“It’s a great honor to have someone of Dr. Arditi’s background and vast knowledge and expertise joining our board,” said Michael Wilhelm, ImmuneRegen’s CEO and Co-Founder. “His background and research on infectious disease will be invaluable in our mission to develop the most effective universal protectant plan from a bioterror attack.”
Other members of the Bioterrorism Preparedness Advisory Board include Captain Dennis Eugene Amundson, MD, Program Director for Pulmonary/Critical Care United States Navy Medical Corps, former U.S.A.F. Surgeon General Dr. Paul K. Carlton, Dr. William E. Hoehn, a legislative and executive veteran of the federal government and a researcher and think tank executive, as well as Michael Caridi, a security industry entrepreneur and major real estate developer. Dr. Arditi will be charged, along with his fellow board members, with developing a plan to disseminate the proprietary and potentially life-saving treatment, Radilex, in the event of a biological or nuclear disaster.
Dr. Arditi is a member of the Society of Pediatric Research, American Academy of Pediatrics, American Society of Microbiology, Infectious Disease Society and the International Endotoxin Society.
Prior to joining Cedars-Sinai, Dr. Arditi was an Associate Professor of Pediatrics at Childrens Hospital Los Angeles. Dr. Arditi received his medical degree from Istanbul University, School of Medicine. He completed his internship and residency in pediatrics at the University of Chicago School of Medicine and a pediatric fellowship at Northwestern University Children’s Memorial Hospital, where he also served as a research associate.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research and development of applications utilizing modified substance P, a naturally occurring immunomodulator. The company’s product, Homspera(TM), is derived from homeostatic substance P. The ongoing focus of ImmuneRegen BioSciences has been the continuing development of Homspera for various applications including the improvement of pulmonary function and the stimulation of the human immune system. The Homspera compound is also being developed as a therapeutic treatment in several other applications including radiation sickness (Radilex(TM)) and viral infection/biological warfare scenarios (Viprovex(TM)). For more information, please visit the company’s website at www.immuneregen.com.
About Radilex(TM)
Radilex is a treatment currently in development for the negative effects of radiation, anthrax, ricin poisoning and other poisonous inhalants. Testing has shown a significant survival rate of radiation exposure at a 7.75 gray level, which is a lethal dosage. Radilex was derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Mark Witten and his associates observed that exposure to jet fuels resulted in pathological changes in the lungs and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs. These studies further showed that the administration of substance P might help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system.
Statements about the Company’s future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company’s actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others.
For Immediate Release Contact: W. Jason Grimley Spelling Communications 310/477-9500 Jgrimley@spellcom.com
ImmuneRegen BioSciences
CONTACT: W. Jason Grimley of Spelling Communications, +1-310-477-9500, orJgrimley@spellcom.com, for ImmuneRegen BioSciences
Web site: http://www.immuneregen.com/
